Patents Represented by Attorney Swiss Tanner, P.C.
-
Patent number: 7875602Abstract: Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.Type: GrantFiled: May 30, 2006Date of Patent: January 25, 2011Assignees: Sutter West Bay Hospitals, Catholic Healthcare WestInventor: Li-Xi Yang
-
Patent number: 7842484Abstract: Disclosed are methods for producing high levels of alcohol during fermentation of plant material, and to the high alcohol beer produced.Type: GrantFiled: February 20, 2007Date of Patent: November 30, 2010Assignee: Poet Research, Inc.Inventor: Stephen M. Lewis
-
Patent number: 7820687Abstract: Disclosed are compounds, which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: July 17, 2009Date of Patent: October 26, 2010Assignee: Elan Pharmaceuticals, Inc.Inventors: Jenifer Smith, Chris Semko, Ying-Zi Xu, Andrei W. Konradi
-
Patent number: 7767820Abstract: Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined hereinType: GrantFiled: May 5, 2008Date of Patent: August 3, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Martin Dimitroff, Bridget R. Miller, Brady S. Stillwell, David A. Siesel, Tyson Swiftney, Brian Diaz, Danlin Gu, Jonathan P. Van Dyck, David Ryckman, Daniel J. Poon, Teresa E. Pick
-
Patent number: 7767697Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.Type: GrantFiled: July 2, 2008Date of Patent: August 3, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Yonghong Song, Zhaozhong J. Jia, Anjali Pandey
-
Patent number: 7763632Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: January 12, 2009Date of Patent: July 27, 2010Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Christopher Michael Semko, Ying-zi Xu, Frank Stappenbeck, Jenifer Lea Smith, Kassandra Inez Rossiter, Juri Y. Fukuda, Andrei W. Konradi
-
Patent number: 7763608Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.Type: GrantFiled: May 4, 2007Date of Patent: July 27, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Yonghong Song, Zhaozhong J. Jia, Anjali Pandey
-
Patent number: 7754710Abstract: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.Type: GrantFiled: April 6, 2007Date of Patent: July 13, 2010Assignee: Novoneuron, Inc.Inventor: Deborah C. Mash
-
Patent number: 7754070Abstract: The disclosed invention is a fixed bed ion exchange water purification system. It employs a combination of electronically controlled process steps and specific systems configurations to duplicate the effects of moving resin beds from one operating position to another as is required in moving bed ion exchange water purification systems. The intention combines features of single fixed bed ion exchange systems with those of a moving bed system. The invention applies to the treatment of water having typical industrial and drinking water concentrations of various ions.Type: GrantFiled: October 31, 2007Date of Patent: July 13, 2010Assignee: Envirogen Technologies, Inc.Inventors: Peter L. Jensen, Gerald A. Guter, Dan Ziol
-
Patent number: 7754071Abstract: The disclosed invention is a fixed bed ion exchange water purification system. It employs a combination of electronically controlled process steps and specific systems configurations to duplicate the effects of moving resin beds from one operating position to another as is required in moving bed ion exchange water purification systems. The invention combines features of single fixed bed ion exchange systems with those of a moving bed system. The invention applies to the treatment of water having typical industrial and drinking water concentrations of various ions.Type: GrantFiled: October 31, 2007Date of Patent: July 13, 2010Assignee: Envirogen Technologies, Inc.Inventors: Peter L. Jensen, Gerald A. Guter, Dan Ziol
-
Patent number: 7749531Abstract: An apparatus and method are provided for visually monitoring, detecting, and/or determining the presence, absence, and/or growth of harmful or potentially harmful bacterial microorganisms beneath a wound dressing, in one example used to cover an indwelling central venous catheter or other catheter. A bacteria detection apparatus includes a barrier membrane, a permeable membrane for placement proximate a wound or a catheter insertion site, and an indicator between the barrier membrane and the permeable membrane for indicating the presence of bacteria proximate the permeable membrane. A method of using a bacterial growth detection apparatus is also provided.Type: GrantFiled: June 8, 2005Date of Patent: July 6, 2010Assignee: Indicator Systems InternationalInventor: Jon Booher
-
Patent number: 7745454Abstract: Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: September 7, 2004Date of Patent: June 29, 2010Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Farouz, Christopher M. Semko, Ying-Zi Xu
-
Patent number: 7741328Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: October 16, 2006Date of Patent: June 22, 2010Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Andrei W. Konradi, Christopher Semko, Ying-Zi Xu
-
Patent number: 7732465Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: December 5, 2008Date of Patent: June 8, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
-
Patent number: 7732595Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph. The A2A-adenosine receptor agonist has the following formula: This compound is prepared by reacting the ethyl ester with methylamine in a sealed pressure reactor.Type: GrantFiled: February 2, 2007Date of Patent: June 8, 2010Assignee: Gilead Palo Alto, Inc.Inventors: Jeff Zablocki, Elfatih Elzein
-
Patent number: 7727996Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: September 28, 2006Date of Patent: June 1, 2010Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Christopher Michael Semko, Ying-zi Xu, Frank Stappenbeck, Jenifer Lea Smith, Kassandra Inez Rossiter, Juri Y. Fukuda, Andrei W. Konradi
-
Patent number: 7727981Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: October 25, 2007Date of Patent: June 1, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
-
Patent number: 7727982Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compound and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: July 17, 2006Date of Patent: June 1, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
-
Patent number: 7722890Abstract: The present invention provides methods of making and using immunogenic oligosaccharide compositions comprising native O-linked and S-linked oligosaccharides coupled to a protein carrier, wherein the resultant conjugate elicits a protectively immunogenic response. These compositions may be useful in vaccines against pathogenic Candida species.Type: GrantFiled: April 25, 2003Date of Patent: May 25, 2010Assignee: Theracarb, Inc.Inventors: David R. Bundle, Mark Nitz, Jim E. Cutler
-
Patent number: 7696352Abstract: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.Type: GrantFiled: January 5, 2007Date of Patent: April 13, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventors: Bing-Yan Zhu, Shawn M. Bauer, Zhaozhong J. Jia, Yonghong Song, Gary D. Probst, Yanchen Zhang, Robert M. Scarborough, Carroll Anna Crew Scarborough, legal representative